Skip to Main content Skip to Navigation
Journal articles

Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma.

Abstract : We present a case of previously unresectable lymphadenopathy in a patient with renal cell carcinoma treated with sunitinib. Complete resection of a 15-cm left renal cell carcinoma was initially impossible due to massive retroperitoneal disease and encasement of the great vessels and mesenteric vessels. Residual retroperitoneal disease from a radical nephrectomy was treated with the oral, multitargeted receptor tyrosine kinase inhibitor, sunitinib. Tumour shrinkage following five cycles of treatment allowed uncomplicated complete resection of the lymphadenopathy. Follow-up after 6 mo showed no evidence of disease recurrence.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00325659
Contributor : Hervé de Villemeur <>
Submitted on : Monday, September 29, 2008 - 7:18:51 PM
Last modification on : Wednesday, August 19, 2020 - 11:16:34 AM

Identifiers

Citation

Jean-Jacques Patard, Rodolphe Thuret, Avakian Raffi, Brigitte Laguerre, Karim Bensalah, et al.. Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma.. European Urology, Elsevier, 2009, 55 (1), pp.237-239. ⟨10.1016/j.eururo.2008.09.006⟩. ⟨inserm-00325659⟩

Share

Metrics

Record views

175